Indication
Oligometastatic Disease
18 clinical trials
24 products
6 drugs
Product
IMSA101Clinical trial
Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist IMSA101 in Patients With Oligometastatic NSCLC and RCCStatus: Recruiting, Estimated PCD: 2025-11-01
Product
Immune checkpoint inhibitorClinical trial
Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) TrialStatus: Recruiting, Estimated PCD: 2026-07-31
Product
Systemic TherapyClinical trial
Perioperative Irinotecan Combined With Oxaliplatin and 5-Fluoracil/Folinic Acid (FOLFIRINOX) For Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma (PHOLIPANC): A Phase II, Open-Label, Single Arm TrialStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Product
FOLFIRINOXClinical trial
Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the PancreasStatus: Recruiting, Estimated PCD: 2024-12-31
Product
nal-irinotecan (nal-iri)Clinical trial
Phase II Study to Assess the Efficacy of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (The ANALLISA Study)Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
NiraparibClinical trial
Phase III Randomized-controlled Study of PD-1 Inhibitor Combined With Local Therapy in Patients With Oligometastatic Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-09-27
Product
PD-1 inhibitorClinical trial
Phase 2 Study of Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy for Patients With Oligometastatic Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-01-01
Product
PD-1Clinical trial
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial PresentationStatus: Terminated, Estimated PCD: 2022-05-03
Drug
DocetaxelClinical trial
A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)Status: Recruiting, Estimated PCD: 2028-12-31
Product
Androgen deprivation therapyClinical trial
Phase 2 Study of Stereotactic Body Radiation Therapy Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Evaluation of Liver MR With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic MetastasesStatus: Recruiting, Estimated PCD: 2024-08-09
Product
Gadoxetate disodiumProduct
Gadobenate dimeglumineClinical trial
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET StudyStatus: Not yet recruiting, Estimated PCD: 2031-01-01
Product
EnzalutamideProduct
DarolutamideProduct
ApalutamideProduct
Lutetium-PSMAClinical trial
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution StudyStatus: Recruiting, Estimated PCD: 2025-05-01
Product
AbirateroneDrug
R-CHOPProduct
Androgen Deprivation TherapyProduct
OlaparibClinical trial
A Multicenter Phase II Randomized Trial to Evaluate Systemic Therapy Versus Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2028-06-01
Product
Maintenance therapyClinical trial
A Phase II Randomized Controlled Trial of TKI Alone Versus TKI and Local Consolidative Radiation Therapy in Oncogene Driver Mutated Oligo Metastatic Non Small Cell Lung Cancer PatientsStatus: Recruiting, Estimated PCD: 2023-11-11
Drug
TKIClinical trial
Standard Maintenance Therapy Versus Local Consolidative Radiation Therapy and Standard Maintenance Therapy in 1-5 Sites of Oligometastatic Non-small Cell Lung Cancer (NSCLC): A Phase III Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-04-20
Product
Standard maintenance therapyClinical trial
Pan-lesions SBRT Combined With Lymphocyte Support Through ATRA-driven Blockade of MDSC in Patients With Oligo-metastatic Solid CancerStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?Status: Recruiting, Estimated PCD: 2027-04-25
Drug
goserelin